• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

16.31 -0.06 (-0.37%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,253,563
Open 16.26
Bid (Size) 16.31 (600)
Ask (Size) 16.49 (100)
Prev. Close 16.37
Today's Range 16.20 - 16.38
52wk Range 12.80 - 16.41
Shares Outstanding 1,557,765,596
Dividend Yield 4.16%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy Intellectual Property

Performance

YTD
+4.4%
+4.4%
1 Month
+14.4%
+14.4%
3 Month
+15.8%
+15.8%
6 Month
+9.9%
+9.9%
1 Year
+23.2%
+23.2%

More News

Read More
News headline image
Earnings Scheduled For October 30, 2025 ↗
October 30, 2025
Via Benzinga
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
January 01, 2026
Via MarketMinute
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
December 23, 2025
Via MarketMinute
Topics Intellectual Property
News headline image
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
December 18, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
December 06, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies ↗
November 21, 2025
Via Stocktwits
News headline image
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗
November 11, 2025
Via Benzinga
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
November 10, 2025
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
November 07, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
Via MarketMinute
Topics Intellectual Property
News headline image
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
November 03, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges ↗
October 30, 2025
Via Benzinga
News headline image
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
October 30, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
October 27, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
October 21, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact ↗
October 14, 2025
Via Benzinga
Topics Artificial Intelligence
News headline image
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗
October 10, 2025
Via Benzinga
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
October 08, 2025
Via MarketMinute
News headline image
What's Going On With Nano-Cap Galecto Stock On Tuesday? ↗
October 07, 2025
Via Benzinga
News headline image
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
September 23, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
5 Best High-Yield Dividend Stocks to Buy Now ↗
September 17, 2025
Via The Motley Fool
News headline image
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
September 16, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
September 11, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire

Frequently Asked Questions

Is Takeda Pharmaceutical Company Limited American Depositary Shares (each publicly traded?
Yes, Takeda Pharmaceutical Company Limited American Depositary Shares (each is publicly traded.
What exchange does Takeda Pharmaceutical Company Limited American Depositary Shares (each trade on?
Takeda Pharmaceutical Company Limited American Depositary Shares (each trades on the New York Stock Exchange
What is the ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each is TAK on the New York Stock Exchange
What is the current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 16.31
When was Takeda Pharmaceutical Company Limited American Depositary Shares (each last traded?
The last trade of Takeda Pharmaceutical Company Limited American Depositary Shares (each was at 01/09/26 07:00 PM ET
What is the market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The market capitalization of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 25.41B
How many shares of Takeda Pharmaceutical Company Limited American Depositary Shares (each are outstanding?
Takeda Pharmaceutical Company Limited American Depositary Shares (each has 25B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap